<DOC>
	<DOC>NCT00605735</DOC>
	<brief_summary>The purpose of this study is to find out if 300 mg of BMS-582949 given once daily will be more effective than placebo after 12 weeks of treatment in subjects with rheumatoid arthritis who are also taking methotrexate</brief_summary>
	<brief_title>PoC in Rheumatoid Arthritis With Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Must have a diagnosis of RA for at least 6 months Must be taking methotrexate for at least 3 months &amp; on a stable dose of 7.530 mg weekly) for 4 weeks before dosing with study medication Must have at least 6 swollen and at least 8 tender joints CRP above upper limit of normal or ESR &gt; 28 mm/hr Must washout (stop taking) other immunosuppressant medications to treat RA (except for methotrexate) before dosing with study medication Any infection including TB, HIV, Hepatitis B or C Recent infection requiring antibiotics within 4 weeks History of gastrointestinal disease (such as GERD, gastrointestinal ulcers, heartburn) requiring medical or surgical treatment within 3 months Chronic use of proton pump inhibitors (such as Losec, Prilosec, Prevacid, Nexium), H2 blockers (such as Tagamet, Pepcid, Zantac, Axid) or antacids (such as Mylanta, Maalox)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>